Aclarion (NASDAQ:ACON) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Aclarion (NASDAQ:ACON) from a hold rating to a sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Aclarion currently has a consensus rating of “Sell”.

Aclarion Stock Performance

ACON opened at $2.58 on Friday. The firm has a market cap of $2.19 million, a price-to-earnings ratio of -0.17 and a beta of 1.44. The firm’s 50-day simple moving average is $4.51 and its 200-day simple moving average is $6.36. Aclarion has a twelve month low of $2.34 and a twelve month high of $229.50.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.